Bladder-Preserving Gemcitabine plus Docetaxel Shows Durable Results After Failed BCG Therapy

Patients whose non-muscle-invasive bladder cancer (NMIBC) persists or returns after treatment with Bacillus Calmette–Guérin (BCG) immunotherapy may have a viable alternative to radical surgery, according to an updated systematic review published in BMC Urology. The analysis, registered with PROSPERO and conducted according to PRISMA guidelines, evaluated sequential intravesical gemcitabine plus docetaxel (Gem/Doce) as a bladder-preserving salvage regimen in patients with BCG-unresponsive disease.

BCG immunotherapy is the cornerstone of adjuvant management for intermediate- and high-risk NMIBC, but 30–40% of patients exhibit BCG-unresponsive disease. For these patients, radical cystectomy remains the standard of care, yet the operation is often declined because of its morbidity and quality-of-life implications. Sequential intravesical gemcitabine plus docetaxel has emerged as a pragmatic bladder-preserving alternative, although the evidence base has remained heterogeneous.

The reviewers searched PubMed, Science Direct, Medline, Embase and Scopus for studies published between January 2009 and October 2025, identifying original clinical studies reported in English that described Gem/Doce outcomes in BCG-unresponsive NMIBC. Risk of bias was assessed with design-specific Joanna Briggs Institute critical appraisal tools. Because the included studies differed substantially in clinical settings and reported outcomes, the findings were synthesized narratively and no quantitative meta-analysis was performed.

Of 521 retrieved articles, 12 studies met the inclusion criteria, encompassing 1,248 patients. One-year recurrence-free survival ranged from 50% to 65% overall, and from 60% to 65% among patients with high-grade disease. At two years, recurrence-free survival ranged from 34% to 46%, with high-grade recurrence-free survival between 30% and 52%.

Longer-term oncological control appeared favorable in the reviewed data. Five-year progression-free survival exceeded 80%, bladder preservation approached 75%, and cancer-specific survival approached 91%. Treatment tolerability was also a notable feature of the evidence: discontinuation for toxicity was reported in fewer than 5% of patients, with adverse effects consisting predominantly of Grade 1–2 urinary symptoms.

Comparative analyses within the review suggested that Gem/Doce achieved outcomes similar to repeat BCG therapy, with potential improvements in progression-free and cystectomy-free survival. The authors caution, however, that these comparisons reflect the heterogeneous, largely retrospective body of literature rather than randomized evidence.

The review’s conclusions are correspondingly measured. Sequential intravesical gemcitabine plus docetaxel seems to offer reproducible oncologic control and excellent tolerability in BCG-unresponsive NMIBC, supporting its role as an accessible salvage regimen when cystectomy is deferred. Nevertheless, the evidence remains largely retrospective and short-term, and the narrative synthesis could not pool effect estimates across studies.

The authors emphasize that future prospective, large multicentre randomised trials with longer follow-up are essential to confirm the durability of the regimen, establish its comparative effectiveness, and define its position within contemporary bladder-preserving treatment algorithms. Until such trials are available, the updated synthesis provides clinicians and patients weighing options after failed BCG therapy with a consolidated summary of the current evidence base and its limitations.

Subject of Research: Sequential intravesical gemcitabine plus docetaxel as a bladder-preserving salvage therapy for BCG-unresponsive non-muscle-invasive bladder cancer

Article Title: Role of sequential intravesical gemcitabine plus docetaxel in refractory/recurrent non-muscle invasive urinary bladder cancer following intravesical BCG: an updated systematic review

Article References: Kumar, L., Srivastava, A., Agarwal, S., Kural, S., Tripathy, R., & Saini, S. (2026). Role of sequential intravesical gemcitabine plus docetaxel in refractory/recurrent non-muscle invasive urinary bladder cancer following intravesical BCG: an updated systematic review. BMC Urology. https://doi.org/10.1186/s12894-026-02318-8

Image Credits: AI Generated

DOI: 10.1186/s12894-026-02318-8

Keywords: bladder cancer, NMIBC, BCG-unresponsive, gemcitabine, docetaxel, intravesical therapy, systematic review, bladder preservation, recurrence-free survival, salvage therapy, BMC Urology, immunotherapy